Efficacy and Safety of Continuous Versus Intermittent Nebulization of Salbutamol in Acute Severe Asthma in Children Under 12 Years of Age

NACompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

September 30, 2024

Study Completion Date

September 30, 2024

Conditions
Asthma in Children
Interventions
DRUG

Continuous Nebulization of Salbutamol

Children received continuous nebulization of salbutamol at a concentration of 0.3 mg/kg/hour for 4 hours, with a minimum of 5 mg/hour and a maximum of 15 mg/hour administered via High Output Extended Aerosol Respiratory Therapy (HEART).

DRUG

Intermittent Nebulization of Salbutamol

were treated with intermittent nebulization of salbutamol at a dose of 0.15 mg/kg/dose, administered through a face mask with an oxygen flow rate of 6-8 L per minute. They Children received at least 2-3 nebulizations and no more than 7.5 mg/dose every 30 minutes for 4 hours.

Trial Locations (2)

66000

Nishtar Hospital, Multan

The Children's Hospital and The Institute of Child Health, Multan

All Listed Sponsors
collaborator

Nishtar Medical University

OTHER

lead

Muhammad Aamir Latif

OTHER

NCT06754631 - Efficacy and Safety of Continuous Versus Intermittent Nebulization of Salbutamol in Acute Severe Asthma in Children Under 12 Years of Age | Biotech Hunter | Biotech Hunter